The US Food and Drug Administration (FDA) has granted regulatory clearance to 4DMedical to market its four-dimensional lung imaging process XV Technology.

The technology is a software-as-a-service (SaaS) diagnostic tool available through secure cloud subscription. It can automatically analyse any functional lung impairment from a single X-ray.

4DMedical founder and CEO Andreas Fouras said: “Our XV Technology is a valuable new respiratory diagnostic tool.

“It provides critical information about the functional and structural state of a patient’s lungs in the treatment of illnesses such as Covid-19, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer.

“FDA clearance means we can fast-track our ‘go-to-market’ strategy to ensure hospitals and doctors in the United States have almost immediate access to our XV Technology Ventilation Reports.”

XV Technology can be deployed immediately, using the existing hospital and clinical infrastructure with no capital expenditure or training required, the company noted.

The process requires imaging departments to electronically send an X-ray, which is taken using existing fluoroscopy equipment, to 4DMedical.